Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Fluorouracil 55Specimen Handling 49Oxaliplatin 48Leucovorin 45Magnetic Resonance Spectroscopy 44Bevacizumab 42Gemcitabine 38Irinotecan 29Cetuximab 27Nivolumab 25130-nm albumin-bound paclitaxel 25Cisplatin 23Biopsy 23pembrolizumab 22Paclitaxel 21Capecitabine 19atezolizumab 18Taxes 14Folfox protocol 13Carboplatin 13durvalumab 12Radiotherapy 12Cyclophosphamide 12fludarabine 11X-Rays 11dehydroftorafur 10Albumin-Bound Paclitaxel 10Surgical Procedures, Operative 9Radiation 9Immunoglobulin G 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
surufatinib × Gastrointestinal × 30 days × Clear all
NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡